Independent. Not owned by or funded by any pharmaceutical manufacturer.
Evidence-sourced · medically-reviewed where indicated
Verification

The November 2026 provider sweep

Evidence-sourced
Written and fact-checked to our published editorial standards.Last updated 2026-11-05. Every clinical claim on this page is sourced to a named primary authority, listed at the foot of the page — see how we research, source, and correct our work.

Direct answer

What you need to know

Evidence strength: Strong

11 of 17 records were re-read against the provider’s own page on 2026-11-05. 3 prices had moved, and every one of them had fallen. The remaining 6 could not be read at all and keep their older dates. The sweep also re-read all 8 FDA labels this site reports on, and that is where it found the more serious problem: 3 of our label dates had been taken from a repackager’s filing rather than the manufacturer’s own. That is an error in how we were reading, not in what we read.

Key takeaways

  • This sweep was due on 2026-10-10 and ran 26 days late. Nothing on the site was wrong because of that, but every figure it carried was older than we promise.
  • All 3 price moves were downward. One provider halved its advertised entry price inside six weeks by withdrawing its entire product line and relaunching it.
  • No clinical finding changed. None of the 8 labels mentions NAION, which is what the lawsuits page says, and the warning flags were confirmed exactly as recorded.

Important limitation: 6 of 17 provider records, two manufacturer prices and one retail chain could not be re-read on this date. Their figures are older than this page, and each says so where it appears.

Next action: The directory carries the result: every provider record with its own date, and every route priced side by side.

Primary sources: Embody (Modern Metabolic Medicine, Inc.), Amazon, Found

General education, not medical advice. Prices change; the date on each record is the date we read it.

It ran 26 days late, which is part of the record

The directory re-checks on a 30-day cadence, and the previous sweep was 10 September, so this one fell due on 2026-10-10. It ran on 2026-11-05. There is no good reason for the gap and no interesting one — nobody ran it.

It is published here because the alternative is a verification date that only ever appears when it flatters us. A directory that re-checks late and says so is worth more than one that re-checks late and rounds the date.

Three prices moved, and all three fell

That is not a pattern we can explain from published terms, and three is far too small a number to call a trend. It is recorded because the direction is uniform and because the previous two sweeps found moves in both directions.

The part that was our fault

The lawsuits page carries a table of all 8 FDA labels for the products named in the gastrointestinal-injury litigation. This sweep re-read every one, and found the method behind it was wrong.

openFDA’s archive holds more than one Structured Product Label per product. Most of the duplicates are filed by repackagers — companies that buy a medicine and relabel it — and a repackager’s filing is a copy of whatever label version it was built from, so it can sit at a different date, and carry different text, from the one the manufacturer publishes. Our reads had been taking whichever SPL the archive returned first.

Three of eight dates in that table were somebody else’s filing, published under the manufacturer’s name.

Ozempic’s row read 30 July 2026, which was A-S Medication Solutions’ filing; Novo Nordisk’s own Ozempic label is dated 30 January 2026. Mounjaro’s read 29 July 2026, also a repackager’s, and in that case the error was not only attribution: Eli Lilly’s own Mounjaro label, effective 27 August 2026, already existed when we read the archive in September and we missed it. The table was out of date as well as misattributed.

The third is the interesting one. Wegovy has no Novo Nordisk filing in that archive at all. The single Wegovy SPL openFDA holds was filed by A-S Medication Solutions in April 2024 under Novo’s application number. The page already made something of Wegovy’s label being the oldest in the set and its silences therefore meaning least; that argument is now both sharper and properly sourced, because the silence belongs to a two-year-old third-party copy rather than to Novo.

Every row now takes the manufacturer’s own label where the archive holds one, and records whose filing it came from. The table says which, and the what the table said before this was found is published in full.

No warning or caution flag changed. The re-read confirmed all of them, and confirmed the finding the page is built on: none of the 8 labels mentions NAION.

Six providers, two manufacturer prices and one chain could not be read

Their records keep the older date and say why, rather than being re-dated because a sweep ran. Two of these changed shape this time.

Delilah is the one worth noting: on the two previous sweeps it served a readable page whose prices were drawn in by the browser afterwards, and this time it returned HTTP 403 to every request. The failure moved from a page without figures to no page at all.

On the manufacturer side, lillydirect.lilly.com, lilly.com and foundayo.lilly.com all returned 403. Zepbound’s $299 self-pay price was confirmed from a Lilly domain that did respond, but Mounjaro’s $499 now stands unre-read since 25 July — the oldest figure on this site — and two rungs of the Foundayo price ladder are temporary and expire on 31 December 2026 with no way for us to confirm they are still in force. CVS returned 403 too, so its $29 visit fee stands as read on 3 September.

What was checked and had not moved

A sweep report that only lists changes makes the unchanged look unchecked. Confirmed against their own pages on 2026-11-05: Calibrate, PlushCare, Ro, WeightWatchers Clinic, Alloy, Fridays, Noom Med and Mochi Health, all with figures identical to September. NovoCare’s Wegovy and Ozempic ladders were confirmed to the dollar, including the 31 December 2026 end dates on the introductory rates. Walgreens’ $49 visit fee and its full advertised medication ladder were confirmed, and that ladder still matches the manufacturer figures read the same day.

When we do this again

The next sweep is due 2026-12-05. If that date has passed and this is still the most recent report, the directory is overdue again and every figure on it should be confirmed before you act on it.

The running log of what changed and when is the provider changes page. The previous report is the September 2026 sweep.

This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.

Sources

Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.

  1. Embody GLP-1 programEmbody (Modern Metabolic Medicine, Inc.)Supports: The flat $49/month and $99/month rates, and the withdrawal of the per-supply product listings, read 5 November 2026.
  2. Amazon GLP-1 management programAmazonSupports: The $199/month injectable cash price and the statement that a One Medical membership is not required, read 5 November 2026.
  3. Found plan pricingFoundSupports: The move from $99/$169 to $79/$149 with medication included on compounded plans, read 5 November 2026.
  4. Structured Product Labeling archiveopenFDA, U.S. Food & Drug AdministrationSupports: All eight labels re-queried with each SPL's filer compared against the named manufacturer, 5 November 2026.